<DOC>
	<DOCNO>NCT01475539</DOCNO>
	<brief_summary>The purpose study generate data support registration extension IMOVAX Polio use sequential vaccination . Primary objective : - To demonstrate non-inferiority Inactivated Poliomyelitis Vaccine ( IPV ) - ( Oral Poliomyelitis Vaccine ) ( OPV ) -OPV ( Sequential 1 ) IPV-IPV-OPV ( sequential 2 ) poliovirus vaccine administration versus OPV-OPV-OPV ( Reference ) term seroprotection rate 28 42 day third dose primary vaccination series . Secondary objective : - To evaluate safety profile investigational vaccine administration group . - To describe humoral immune response poliovirus serotypes ( type 1 , 2 3 ) first dose 28 42 day third primary series dose vaccine group . - To describe persistence antibody poliovirus serotypes ( type 1 , 2 3 ) third primary series dose administration , 18 month age group .</brief_summary>
	<brief_title>Sequential Inactivated Poliomyelitis Vaccine Followed Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine</brief_title>
	<detailed_description>Study participant randomize receive either 3 dos commercially available Oral Poliovirus Vaccine ( OPV ) , 1 dose Sanofi Pasteur 's injectable Inactivated Poliovirus Vaccine IMOVAX Polio ( IPV ) follow 2 dos OPV , 2 dos IPV follow 1 dose OPV . These vaccine administer 2 , 3 4 month age primary vaccination prevention poliomyelitis . Participants follow 18th- 19th-month birthday .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged ≥2 month le 3 month day first study vaccine administration Born full term pregnancy ( ≥37 week ) birth weight ≥2.5 kg Informed consent form sign dated parent legally acceptable representative Subject parent/legally acceptable representative able attend schedule visit comply trial procedure . Participation 4 week precede first trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt plan receipt vaccine 4 week precede follow trial vaccination ( except Diphtheria , Tetanus , acellular Pertussis vaccine [ DTaP ] , Haemophilus Influenzae Type b [ Hib ] vaccine , bacille CalmetteGuerin vaccine [ BCG ] Hepatitis B give least 7 day study vaccination ) Previous vaccination poliomyelitis either trial vaccine another vaccine Receipt immune globulin , blood bloodderived product since birth Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy since birth ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week since birth ) Congenital acquire immunodeficiency close contact subject History poliomyelitis infection ( confirm either clinically , serologically microbiologically ) At high risk human immunodeficiency virus ( HIV ) infection trial Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Laboratoryconfirmed otherwise know thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( axillary temperature ≥37.1°C ) . A prospective subject include study condition resolve febrile event subside Identified natural adopt child Investigator employee direct involvement propose study Any contraindication list study vaccine ' leaflet .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>2 Months</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Polio</keyword>
	<keyword>Poliovirus</keyword>
	<keyword>Oral poliovirus vaccine</keyword>
	<keyword>IMOVAX Polio®</keyword>
</DOC>